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Aim: To investigate associations between patatin-like phospholipase domain-containing 3 (PNPLA3) genotypes and
fibrosis and hepatocarcinogenesis in Japanese chronic hepatitis C (CHC) patients.
Methods: Two hundred and thirty-one patients with CHC were examined for PNPLA3 genotypes, liver stiffness
measurements (LSM), and hepatocellular carcinoma (HCC) from May 2010 to October 2012 at Fujita Health University
Hospital. The rs738409 single nucleotide polymorphism (SNP) encoding for a functional PNPLA3 I148M protein variant
was genotyped using a TaqMan predesigned SNP genotyping assay. LSM was determined as the velocity of a shear
wave (Vs) with an acoustic radiation force impulse. Vs cut-off values for cirrhosis were set at 1.55 m/s. We excluded
CHC patients with a sustained virological response or relapse after interferon treatment.
Results: PNPLA3 genotypes were CC, CG, and GG for 118, 72, and 41 patients, respectively. Multivariable logistic
regression analysis selected older age (OR = 1.06; 95% CI: 1.03–1.09; p < 0.0001), higher body mass index (BMI)
(OR= 1.12; 95% CI: 1.03–1.22; p = 0.0082), and PNPLA3 genotype GG (OR = 2.07; 95% CI: 0.97–4.42; p = 0.0599) as the
factors independently associated with cirrhosis. When 137 patients without past history of interferon treatment
were separately assessed, multivariable logistic regression analysis selected older age (OR = 1.05; 95% CI: 1.02–1.09;
p = 0.0034), and PNPLA3 genotype GG (OR = 3.35; 95% CI: 1.13–9.91; p = 0.0291) as the factors independently
associated with cirrhosis. Multivariable logistic regression analysis selected older age (OR = 1.12; 95% CI: 1.07–1.17;
p < 0.0001), PNPLA3 genotype GG (OR = 2.62; 95% CI: 1.15–5.96; p = 0.0218), and male gender (OR = 1.83; 95% CI:
0.90–3.71); p = 0.0936) as the factors independently associated with HCC.
Conclusion: PNPLA3 genotype I148M is one of risk factors for developing HCC in Japanese CHC patients, and is one of
risk factors for progress to cirrhosis in the patients without past history of interferon treatment.
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It is estimated that 130–170 million people, appro-
ximately 2%–3% of the world’s population, are infected
with the hepatitis C virus (HCV) (Shepard et al. 2005).
Of the >500,000 new cases of hepatocellular carcinoma
(HCC) that occur each year, approximately 25% are* Correspondence: kyoshiok@fujita-hu.ac.jp
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in any medium, provided the original work is pattributable to HCV infection (Block et al. 2003). In
Japan, there are an estimated 880,000 HCV carriers aged
16–69 years, and 33,000 deaths occurred each year be-
cause of HCC, 81% of which were attributed to HCV in-
fection (Yoshizawa et al. 2006). Treatments for chronic
hepatitis C (CHC) have improved and the sustained
virological response (SVR) rate has increased to 73%–
86% (Fried et al. 2013; Wada et al. 2014). However, HCC
still occurs in a large number of HCV carriers. There-
fore, the elucidation of factors associated with thean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Vs values among PNPLA3 genotypes. Vs values tended
to be higher for patients with GG than for those with CG (p = 0.0636)
and was higher than for those with CC, although there was no
statistically significant difference.
Figure 2 Frequencies of hepatocellular carcinoma among
PNPLA3 genotypes. The hepatocellular carcinoma frequency was
higher for patients with GG than for those with CG or for those with
CC, although there was no statistically significant difference.
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continued.
The rs738409 single nucleotide polymorphism (SNP) en-
coding for a functional I148M protein variant of the
patatin-like phospholipase domain-containing 3 (PNPLA3,
adiponutrin) gene is associated with hepatic steatosis, in-
flammation, fibrosis, and carcinogenesis in nonalcoholic
fatty liver disease (NAFLD) (Romeo et al. 2008; Rotman
et al. 2010; Kawaguchi et al. 2012; Kitamoto et al. 2013).
This PNPLA3 gene polymorphism has also been reported
to be associated with hepatic steatosis, fibrosis, treatment
response, and carcinogenesis with CHC (Valenti et al.
2011; Trepo et al. 2011; Cai et al. 2011; Valenti et al. 2012;
Clark et al. 2012; Dunn et al. 2014; Ezzikouri et al. 2014;
Moritou et al. 2013; Zampino et al. 2013; Trepo et al.
2014; Sato et al. 2013). However, several reports did not
find an association of this PNPLA3 gene polymorphism
and some pathological features in CHC (Trepo et al. 2011;
Nischalke et al. 2011; Rembeck et al. 2012; Miyashita et al.
2012; Takeuchi et al. 2013; Nakamura et al. 2013; Guyot
et al. 2013). Therefore, the association of this PNPLA3
gene polymorphism and pathological features remains to
be validated.
Although liver biopsy is the gold standard for diagnos-
ing liver fibrosis, it is an invasive procedure and incurs a
high cost. Therefore, it is difficult to perform liver biop-
sies when numerous patients are involved. However,
noninvasive methods have been developed to assess liver
fibrosis. Liver stiffness measurements (LSM) by transient
elastography (TE) with a Fibroscan (Arima et al. 2010)
and the velocity of a shear wave (Vs) measured by an
acoustic radiation force impulse (ARFI) (Friedrich-Rust
et al. 2009; Nishikawa et al. 2014) are correlated with
the liver fibrosis stage in various liver diseases.
In the present study, we investigated possible associa-
tions of a PNPLA3 gene polymorphism with fibrosis and
the development of HCC in Japanese patients with
CHC. We used ARFI to assess hepatic fibrosis.
Results
PNPLA3 genotypes
For PNPLA3 (rs738409 C > G) genotypes, 118 patients
had CC, 72 had CG, and 41 had GG. The G allele fre-
quency was 33.3%. Vs values tended to be higher for pa-
tients with GG than for those with CG (p = 0.0636) and
were higher than for those with CC, although there was
no statistically significant difference (Figure 1). The fre-
quency of HCC was higher among patients with GG
than among those with CG or CC, although there was
no statistically significant difference (Figure 2). There-
fore, subsequent comparisons were made between pa-
tients with GG and those with CG or CC.
The patients with GG tended to have higher aspartate
aminotransferase (AST) levels (p = 0.0946) and higher
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lower platelet counts (p = 0.0276), lower prothrom-
bin times (p = 0.0407), higher hyaluronic acid levels
(p = 0.0365), higher Vs values (p = 0.0126), and a higher
frequency of HCC (p = 0.0200) than those with CG or
CC (Table 1).
Factors associated with cirrhosis estimated by ARFI
Vs cut-off values for cirrhosis were set at 1.55 m/s, based
on a report by Sporea et al.(Sporea et al. 2012). A total of
117 patients had Vs values of ≥ 1.55 m/s and were consid-
ered to have liver cirrhosis. As shown in Table 2, cirrhosis
was associated with older age (p < 0.0001), higher body
mass index (BMI) values (p = 0.0281), PNPLA3 genotype
GG (p = 0.0318), higher AST levels (p < 0.0001), higher
alanine aminotransferase (ALT) levels (p = 0.0195),
lower albumin levels (p < 0.0001), lower platelet counts
(p < 0.0001), lower prothrombin times (p < 0.0001), higher
hyaluronic acid levels (p < 0.0001), higher α-fetoprotein
(AFP) levels (p = 0.0452), higher protein induced by the
vitamin K absence or antagonist-II (PIVKA-II) levels
(p = 0.0023), HCV genotype 1 (p = 0.0283), and the pre-
sence of HCC (p < 0.0001).
Factors possibly associated with the progression to cir-
rhosis were assessed by multivariable regression analysisTable 1 Characteristics of 231 patients studied and compariso
All patients P
(n = 231) (n
Age (yrs) 62.9 ± 11.3 6
Gender (male/female) 103/128 1
BMI (kg/m2) 22.5 ± 3.5 2
Response to IFN treatment (NVR/no past IFN therapy) 94/137 1
PNPLA3 (GG/CG/CC) 41/118/72
AST (IU/L) 57.0 ± 48.8 6
ALT (IU/L) 62.9 ± 76.1 6
γ-GTP (IU/L) 58.9 ± 78.1 6
Albumin (g/dL) 4.1 ± 0.6 4
Total bilirubin (mg/dL) 1.0 ± 0.8 1
Platelet count (x104/μL) 13.4 ± 5.6 1
Prothrombin time (%) 94.3 ± 18.6 8
Hyaluronic acid (ng/mL) 236.6 ± 337.7 3
α-fetoprotein (ng/mL) 79.1 ± 529.3 6
PIVKA-II(mAU/mL) 24.7 ± 23.1 2
HCV genotype (1/2/3) 188/41/2 3
HCV RNA (log IU/mL) 6.1 ± 1.0 6
Velocity of shear wave (m/s) 1.66 ± 0.52 1
Hepatocellular carcnoma (present/absent) 48/183 1
PNPLA3, patatin-like phospholipase domain-containing 3; BMI, body mass index; IFN
ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein ind
NS, not significant.(Table 2). These factors included age, gender, BMI,
PNPLA3 genotype, and HCV genotype. AST, ALT, albu-
min, platelet count, prothrombin time, hyaluronic acid,
AFP, and PIVKA-II that were associated with cirrhosis
by univariate analyses were excluded because they were
apparently the result of cirrhosis but not the causes for
the progression to cirrhosis. Because gender was reported
to be associated with progression to cirrhosis (Poynard
et al. 1997), gender, which was not associated with cirrho-
sis by univariate analysis, was included among the factors
possibly associated with progression to cirrhosis. This ana-
lysis showed that older age (OR = 1.06; 95% CI: 1.03–1.09;
p < 0.0001), higher BMI values (OR = 1.12; 95% CI: 1.03–
1.22; p = 0.0082), and PNPLA3 genotype GG (OR = 2.07;
95% CI: 0.97–4.42; p = 0.0599) were factors indepen-
dently associated with progression to cirrhosis, although
the association with PNPLA3 genotype GG was only a
tendency.
One hundred thirty seven patients without past history
of interferon (IFN) treatment were separately assessed.
Cirrhosis was associated with age (p = 0.0011), PNPLA3
genotype (p = 0.0113), AST levels (p < 0.0001), ALT
levels (p = 0.0027), albumin levels (p < 0.0001), total bili-
rubin levels (p = 0.0078), platelet counts (p < 0.0001),
prothrombin times (p = 0.0002), hyaluronic acid levelsn among PNPLA3 genotypes
atients with GG Patients with CC or CG Comparison between
patients with GG and
those with CG or CG
= 41) (n = 190)
3.8 ± 10.6 62.7 ± 11.5 NS
9/22 84/106 NS
3.3 ± 3.6 22.3 ± 3.5 NS
9/22 75/115 NS
8.5 ± 61.9 54.5 ± 45.3 p = 0.0946
3.8 ± 51.6 62.7 ± 80.5 NS
0.6 ± 63.5 58.5 ± 81.0 NS
.0 ± 0.6 4.1 ± 0.6 NS
.2 ± 0.8 0.9 ± 0.8 p = 0.0876
1.7 ± 5.4 13.8 ± 5.5 p = 0.0276
8.9 ± 17.7 95.5 ± 18.7 p = 0.0407
40.5 ± 490.3 214.5 ± 292.3 p = 0.0365
6.3 ± 193.5 81.9 ± 578.0 NS
9.3 ± 36.4 23.7 ± 18.9 NS
4/7/0 150/37/2 NS
.1 ± 1.3 6.1 ± 1.0 NS
.91 ± 0.70 1.65 ± 0.57 p = 0.0126
4/27 22/96 p = 0.0200
, interferon; NVR, non-virological response; AST, aspartate aminotransferase;
uced by Vitamin K absence or antagonist-II; Vs, velocity of shear wave;
Table 2 Comparison between the patients with Vs < 1.55 m/s and those with Vs ≧ 1.55 m/s in all the 231 patients
Patients with
Vs ≧ 1.55 m/s
Patients with
Vs < 1.55 m/s
Comparison between
patients with Vs < 1.55 m/s
and those with Vs ≧ 1.55 m/s
Multiple regression analysis for
factors associated with ≧ 1.55 m/s
(n = 117) (n = 114) Odds ratio (95%
confidence interval)
p
Age (yrs) 66.1 ± 10.0 60.0 ± 11.6 p < 0.0001 1.06 (1.03 - 1.09) p < 0.0001
Gender (male/female) 51/66 52/62 NS NS
BMI (kg/m2) 23.0 ± 3.7 22.0 ± 3.2 p = 0.0281 1.12 (1.03 - 1.22) p = 0.0082
Response to IFN treatment
(NVR/no past IFN therapy)
45/72 49/65 NS
PNPLA3 (GG/CC・CG) 27/90 14/100 p = 0.0318 2.07 (0.97 - 4.42) p = 0.0599
AST (IU/L) 70.2 ± 47.3 42.4 ± 46.4 p < 0.0001
ALT (IU/L) 74.0 ± 79.0 50.64 ± 71.3 p = 0.0195
γ-GTP (IU/L) 61.2 ± 50.2 56.4 ± 100.4 NS
Albumin (g/dL) 3.8 ± 0.7 4.4 ± 0.4 p < 0.0001
Total bilirubin (mg/dL) 1.03 ± 0.56 0.87 ± 1.05 NS
Platelet count (x104/μL) 10.7 ± 4.4 16.3 ± 5.2 p < 0.0001
Prothrombin time (%) 88.0 ± 14.8 101.2 ± 20.0 p < 0.0001
Hyaluronic acid (ng/mL) 348.1 ± 330.7 123.0 ± 306.7 p < 0.0001
α-fetoprotein (ng/mL 146.0 ± 726.0 5.30 ± 5.2 p = 0.0452
PIVKA-II(mAU/mL) 29.3 ± 29.8 20.0 ± 10.9 p = 0.0023
HCV genotype (1/2/3) 101/14/2 87/27/0 p = 0.0283 NS
HCV RNA (log IU/mL) 6.2 ± 0.9 6.1 ± 1.1 NS
Velocity of shear wave (m/s) 1.98 ± 0.46 1.27 ± 0.26 p < 0.0001
Hepatocellular carcnoma
(present/absent)
42/75 6/108 p < 0.0001
Vs, velocity of shear wave; BMI, body mass index; IFN, interferon; NVR, non-virological response; PNPLA3, patatin-like phospholipase domain-containing 3;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II ;
NS, not significant.
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(p = 0.0072), and the presence of HCC (p < 0.0001)
(Table 3). Age, gender, and PNPLA3 genotype were
assessed for the factors possibly associated with the pro-
gression to cirrhosis by multivariable regression analysis
(Table 3). This analysis showed that older age (OR = 1.05;
95% CI: 1.02–1.09; p = 0.0034), and PNPLA3 genotype
GG (OR = 3.35; 95% CI: 1.13–9.91; p = 0.0291) were
factors independently associated with progression to
cirrhosis.
Ninety four patients with non-virological response
(NVR) of past IFN treatment were separately assessed.
Cirrhosis was associated with age (p = 0.0026), BMI
values (p = 0.0274), albumin levels (p < 0.0001), platelet
counts (p < 0.0001), prothrombin times (p < 0.0001), hya-
luronic acid levels (p < 0.0001), AFP levels (p < 0.0001),
and the presence of HCC (p = 0.0017) (Table 4). Age, gen-
der, and BMI were assessed for the factors possibly asso-
ciated with the progression to cirrhosis by multivariable
regression analysis (Table 4). This analysis showed that
older age (OR = 1.08; 95% CI: 1.03–1.13; p = 0.0023),and higher BMI values (OR = 1.20; 95% CI: 1.04–1.39;
p = 0.0156) were factors independently associated with
progression to cirrhosis.
Factors associated with the development of HCC
As shown in Table 5, HCC was associated with older age
(p < 0.0001), PNPLA3 genotype GG (p = 0.0200), higher
AST levels (p = 0.0158), lower albumin levels (p < 0.0001),
higher total bilirubin levels (p = 0.0010), lower platelet
counts (p < 0.0001), lower prothrombin times (p < 0.0001),
higher hyaluronic acid levels (p < 0.0001), higher AFP
levels (p = 0.0009), higher PIVKA-II levels (p = 0.0030),
and higher Vs values (p < 0.0001).
Factors possibly associated with the development of
HCC were assessed by multivariable regression analysis
(Table 5). These factors included age, gender, and
PNPLA3 genotype. AST, albumin, total bilirubin, platelet
count, prothrombin time, hyaluronic acid, AFP, PIVKA-II,
and Vs that were associated with HCC by univariate
analyses were excluded because they were apparently the
result of cirrhosis, which is a major risk factor for HCC,
Table 3 Comparison between the patients with Vs < 1.55 m/s and those with Vs ≧ 1.55 m/s in the 137 patients without
past history of IFN treatment
Patients with
Vs ≧ 1.55 m/s
Patients with
Vs < 1.55 m/s
Comparison between
patients with Vs < 1.55 m/s
and those with Vs ≧ 1.55 m/s
Multiple regression analysis for
factors associated with ≧ 1.55 m/s
(n = 72) (n = 65) Odds ratio (95%
confidence interval)
p
Age (yrs) 67.3±10.3 60.9±12.0 P = 0.0011 1.05 (1.02 - 1.09) p = 0.0034
Gender (male/female) 33/39 31/34 NS NS
BMI (kg/m2) 22.6±3.6 21.7±3.4 NS
PNPLA3 (GG/CC・CG) 17/55 5/60 P = 0.0113 3.35 (1.13 - 9.91) p = 0.0291
AST (IU/L) 76.7±56.2 37.3±28.4 p < 0.0001
ALT (IU/L) 82.9±96.2 43.6±41.1 P = 0.0027
γ-GTP (IU/L) 64.0±57.3 51.9±77.1 NS
Albumin (g/dL) 3.7±0.6 4.3±0.4 p < 0.0001
Total bilirubin (mg/dL) 1.1±0.7 0.8±0.6 P = 0.0078
Platelet count (x104/μL) 10.4±4.5 15.9±5.3 p < 0.0001
Prothrombin time (%) 87.1±15.4 99.1±21.5 P = 0.0002
Hyaluronic acid (ng/mL) 385.0±383.0 148.8±371.4 P = 0.0006
α-fetoprotein (ng/mL) 233.9±939.1 6.8±10.8 P = 0.0553
PIVKA-II(mAU/mL) 32.9±36.1 20.0±11.9 P = 0.0072
HCV genotype (1/2/3) 61/10/1 48/17/0 NS
HCV RNA (log IU/mL) 6.0±0.9 6.2±1.3 NS
Velocity of shear wave (m/s) 2.14±0.46 1.23±1.0 p < 0.0001
Hepatocellular carcnoma (present/absent) 28/44 3/62 p < 0.0001
Vs, velocity of shear wave; BMI, body mass index; IFN, interferon; PNPLA3, patatin-like phospholipase domain-containing 3; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II ; NS, not significant.
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Because gender was reported to be associated with the de-
velopment of HCC (Asahina et al. 2010), gender, which
was not associated with HCC by univariate analysis, was
included for multivariable analysis. This analysis showed
that older age (OR = 1.12; 95% CI: 1.07–1.17; p < 0.0001),
PNPLA3 genotype GG (OR = 2.62; 95% CI: 1.15–5.96;
p = 0.0218), and male gender (OR = 1.83; 95% CI: 0.90–
3.71; p = 0.0936) were factors independently associated
with the development of HCC, although the association
with gender was only a tendency.
One hundred thirty seven patients without past history of
IFN treatment were separately assessed. HCC was associ-
ated with age (p = 0.0002), PNPLA3 genotype (p = 0.0928),
AST levels (p = 0.0032), albumin levels (p < 0.0001), total
bilirubin levels (p < 0.0001), platelet counts (p = 0.0008),
prothrombin times (p = 0.0002), hyaluronic acid levels
(p = 0.0002), AFP levels (p = 0.0016), PIVKA-II levels
(p < 0.0001), and Vs values (p < 0.0001) (Table 6). Age,
gender, and PNPLA3 genotype were assessed for factors
possibly associated with the development of HCC by mul-
tivariable regression analysis (Table 6). This analysis
showed that older age (OR = 1.09; 95% CI: 1.04–1.15;p = 0.0006) was an only factor independently associated
with the development of HCC.
Ninety four patients with NVR of past IFN treatment
were separately assessed. HCC was associated with age
(p < 0.0001), PNPLA3 genotype (p = 0.0871), albumin
levels (p < 0.0001), platelet counts (p = 0.0008), prothrom-
bin times (p = 0.0295), hyaluronic acid levels (p = 0.0002),
AFP levels (p = 0.0005), PIVKA-II levels (p = 0.0134), and
Vs values (p = 0.0002) (Table 7). Age, gender, and
PNPLA3 genotype were assessed for the factors possibly
associated with the development of HCC by multivariable
regression analysis (Table 7). This analysis showed that
older age (OR = 1.19; 95% CI: 1.08–1.32; p = 0.0007), and
PNPLA3 genotype GG (OR = 3.95; 95% CI: 1.00–15.61;
p = 0.0497) were factors independently associated with
the development of HCC.
Discussion
In this study, we demonstrated that a PNPLA3 gene
polymorphism was associated with the progression of
fibrosis to cirrhosis and development of HCC, although
the association with cirrhosis was only a tendency by
multivariable analysis in all the 231 patients studied.
Table 4 Comparison between the patients with Vs < 1.55 m/s and those with Vs ≧ 1.55 m/s in the 94 patients with
NVR of past IFN treatment
Patients with
Vs ≧ 1.55 m/s
Patients with
Vs < 1.55 m/s
Comparison between
patients with Vs < 1.55 m/s
and those with Vs ≧ 1.55 m/s
Multiple regression analysis for
factors associated with ≧ 1.55 m/s
(n = 45) (n = 49) Odds ratio (95%
confidence interval)
p
Age (yrs) 64.3±9.4 57.7±10.9 P = 0.0026 1.03 (1.03 - 1.13) p = 0.0023
Gender (male/female) 18/27 21/28 NS NS
BMI (kg/m2) 23.7±3.8 22.2±2.8 P = 0.0274 1.20 (1.04 - 1.39) p = 0.0156
PNPLA3 (GG/CC・CG) 10/35 9/40 NS
AST (IU/L) 59.6±22.0 51.7±63.9 NS
ALT (IU/L) 58.6±31.2 62.8±98.8 NS
γ-GTP (IU/L) 57.2±37.1 62.1±122.7 NS
Albumin (g/dL) 3.9±0.7 4.4±0.3 p < 0.0001
Total bilirubin (mg/dL) 0.9±0.3 1.0±1.4 NS
Platelet count (x104/μL) 11.1±4.4 16.7±5.1 p < 0.0001
Prothrombin time (%) 88.5±14.1 104.0±16.5 p < 0.0001
Hyaluronic acid (ng/mL) 305.2±229.7 89.3±170.5 p < 0.0001
α-fetoprotein (ng/mL) 20.1±18.0 4.9±3.6 p < 0.0001
PIVKA-II(mAU/mL) 23.5±13.9 19.9±9.3 NS
HCV genotype (1/2/3) 40/4/1 39/10/0 NS
HCV RNA (log IU/mL) 6.3±0.9 6.0±1.3 NS
Velocity of shear wave (m/s) 2.20±0.50 1.23±0.16 p < 0.0001
Hepatocellular carcnoma (present/absent) 14/31 3/46 P = 0.0017
NVR, non-virological response; IFN, interferon; Vs, velocity of shear wave; BMI, body mass index; PNPLA3, patatin-like phospholipase domain-containing 3;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II ;
NS, not significant.
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with NVR of past IFN treatment were separately ana-
lyzed, a PNPLA3 gene polymorphism was selected as a
factor independently associated with progression to cir-
rhosis in those without previous IFN treatment but not
in those with NVR of past IFN treatment. A PNPLA3
gene polymorphism was selected as a factor independ-
ently associated with development to HCC in those with
NVR of past IFN treatment but not in those without
past IFN treatment.
PNPLA3 polymorphisms have been reported to be as-
sociated with hepatic steatosis, inflammation, fibrosis,
and carcinogenesis in NAFLD (Romeo et al. 2008;
Rotman et al. 2010; Valenti et al. 2010; Sookoian and
Pirola 2011; Burza et al. 2012; Kawaguchi et al. 2012;
Kitamoto et al. 2013). PNPLA3 polymorphisms have also
been reported to be associated with hepatic steatosis,
fibrosis, treatment response, and carcinogenesis in CHC
(Valenti et al. 2011; Trepo et al. 2011; Cai et al. 2011;
Valenti et al. 2012; Clark et al. 2012; Dunn et al. 2014;
Ezzikouri et al. 2014; Moritou et al. 2013; Zampino et al.
2013; Trepo et al. 2014; Sato et al. 2013). However,several reports have not found an association of
PNPLA3 polymorphisms with fibrosis and carcinogen-
esis in CHC (Trepo et al. 2011; Nischalke et al. 2011;
Rembeck et al. 2012; Miyashita et al. 2012; Takeuchi
et al. 2013; Nakamura et al. 2013; Guyot et al. 2013).
A significant association was reported between a
PNPLA3 polymorphism and HCC in patients with CHC
(Valenti et al. 2011; Ezzikouri et al. 2014), while other
studies did not find a significant association(Nischalke
et al. 2011; Guyot et al. 2013). A meta-analysis performed
by Trepo et al. showed that a PNPLA3 polymorphism was
strongly associated with HCC, although the association
was stronger in patients with alcoholic liver disease
(OR = 2.20; 95% CI: 1.802.67; P = 4.71 × 10−15) than that
in patients with CHC (OR = 1.55; 95% CI: 1.03–2.34;
P = 3.52 × 10−2) (Trepo et al. 2014). In Japanese studies,
Moritou et al. reported that a PNPLA3 polymorphism was
significantly associated with serum AFP level (Moritou
et al. 2013), and Sato et al. reported that the median time
between HCV infection and the development of HCC was
significantly shorter for patients with the PNPLA3 GG
genotype in HCV-related HCC (Sato et al. 2013). The






patients with HCC and
those without HCC
Multiple regression analysis for factors
associated with HCC development
(n = 48) (n = 183) Odds ratio (95%
confidence interval)
p
Age (yrs) 70.5 ± 7.8 60.9 ± 11.2 p < 0.0001 1.12 (1.07 - 1.17) p < 0.0001
Gender (male/female) 25/23 78/105 NS 1.83 (0.90 - 3.71) p = 0.0936
BMI (kg/m2) 23.1 ± 3.9 22.3 ± 3.4 NS
Response to IFN treatment
(NVR/no past IFN therapy)
17/31 77/106 NS
PNPLA3 (GG/CC・CG) 34/14 156/27 p = 0.0200 2.62 (1.15 - 5.96) p = 0.0218
AST (IU/L) 72.1 ± 54.8 53.0 ± 46.4 p = 0.0158
ALT (IU/L) 60.4 ± 46.4 63.5 ± 82.1 NS
γ-GTP (IU/L) 50.4 ± 34.9 61.1 ± 85.8 NS
Albumin (g/dL) 3.5 ± 0.7 4.2 ± 0.5 p < 0.0001
Total bilirubin (mg/dL) 1.3 ± 0.97 0.9 ± 0.76 p = 0.0010
Platelet count (x104/μL) 9.5 ± 4.2 14.4 ± 5.4 p < 0.0001
Prothrombin time (%) 83.7 ± 13.90 97.1 ± 18.8 p < 0.0001
Hyaluronic acid (ng/mL) 473.8 ± 480.9 181.1 ± 267.2 p < 0.0001
α-fetoprotein (ng/mL) 308.6 ± 1134.9 20.8 ± 113.2 p = 0.0009
PIVKA-II(mAU/mL) 40.25 ± 43.22 20.56 ± 9.93 p = 0.0030
HCV genotype (1/2/3) 42/6/0 169/35/2 NS
HCV RNA (log IU/mL) 6.0 ± 1.1 6.2 ± 1.0 NS
Velocity of shear wave (m/s) 2.19 ± 0.64 1.57 ± 0.52 p < 0.0001
HCC, hepatocellular carcinoma; BMI, body mass index; IFN, interferon; NVR, non-virological response; PNPLA3, patatin-like phospholipase domain-containing 3;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II;
NS, not significant.
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between PNPLA3 and the development of HCC in
Japanese patients.
In this study, we demonstrated that a PNPLA3 poly-
morphism was associated with the progression of fi-
brosis to cirrhosis. The association was significant by
multivariable analysis in the patients without past IFN
treatment, while it was only a tendency by analysis in all
the 231 patients studied.
Several studies reported that a PNPLA3 polymorphism
was associated with fibrosis in patients with CHC
(Valenti et al. 2011; Trepo et al. 2011; Valenti et al. 2012;
Dunn et al. 2014), while other studies did not find an as-
sociation between a PNPLA3 polymorphism and fibrosis
(Zampino et al. 2013; Rembeck et al. 2012; Miyashita
et al. 2012; Nakamura et al. 2013).
These discrepancies reported on the association of
PNPLA3 with the development of HCC or fibrosis
may be attributed to the difference of the ethnicity,
population, and past treatment of the patients studied.
In our study, the patients with SVR and relapse of past
IFN treatment were excluded, because their LSM results
declined and the risk of the development of HCC alsowas reduced (Arima et al. 2010; Kasahara et al. 1998;
Harada et al. 2014). Because the associations of PNPLA3
are not strong for fibrosis (OR = 3.13; 95% CI: 1.50–6.51;
P = 0.002) (Trepo et al. 2011) and development of HCC
(Trepo et al. 2014), a large number of more homogenous
patients should be studied to establish an association by
statistical analysis. The present study included 231 pa-
tients, and the association between fibrosis and PNPLA3
was shown to be only a tendency by multivariable analysis,
while the association was shown by multivariable analysis
of the patients without past IFN treatment.
In our present study, we diagnosed cirrhosis on the
basis of Vs values rather than by liver biopsy. Some stu-
dies reported that an association between Vs values and
fibrosis is affected by inflammation (Chen et al. 2012;
Yoon et al. 2012), although others denied this asso-
ciation (Bota et al. 2013; Nishikawa et al. 2014; Rizzo
et al. 2011). To confirm this association between fibrosis
and PNPLA3 in Japanese patients, further studies using
liver biopsies are required.
Nishikawa et al. reported that Vs values were nega-
tively correlated with BMI in the patients with fibrosis
stage F1 or F2, but not in those with F3 or F4
Table 6 Comparison between the patients with HCC and those without HCC in the 137 patients without past history of
IFN treatment
Patients with HCC Patients without HCC Comparison between
patients with HCC and
those without HCC
Multiple regression analysis for factors
associated with HCC development
(n = 31) (n = 106) Odds ratio (95%
confidence interval)
p
Age (yrs) 70.9±7.1 62.3±11.9 P = 0.0002 1.09 (1.04 - 1.15) p = 0.0006
Gender (male/female) 16/15 48/58 NS NS
BMI (kg/m2) 23.1±4.0 21.9±3.4 NS
PNPLA3 (GG/CC・CG) 8/23 14/92 P = 0.0928 NS
AST (IU/L) 80.7±64.3 51.4±41.8 P = 0.0032
ALT (IU/L) 65.5±50.0 63.9±84.1 NS
γ-GTP (IU/L) 53.5±40.7 60.0±73.6 NS
Albumin (g/dL) 3.4±0.56 4.2±0.5 p < 0.0001
Total bilirubin (mg/dL) 1.5±1.1 0.8±0.4 p < 0.0001
Platelet count (x104/μL) 9.2±4.3 14.1±5.5 P = 0.0008
Prothrombin time (%) 81.5±14.0 96.0±19.7 P= 0.0002
Hyaluronic acid (ng/mL) 507.0±542.5 202.1±313.7 P = 0.0002
α-fetoprotein (ng/mL) 475.9±1411.2 28.7±148.1 P = 0.0016
PIVKA-II(mAU/mL) 47.0±51.0 20.8±10.7 p < 0.0001
HCV genotype (1/2/3) 27/4/0 82/23/1 NS
HCV RNA (log IU/mL) 5.9±1.0 6.2±0.9 NS
Velocity of shear wave (m/s) 2.20±0.70 1.55±0.50 p < 0.0001
HCC, hepatocellular carcinoma; IFN, interferon; BMI, body mass index; NVR, non-virological response; PNPLA3, patatin-like phospholipase domain-containing 3;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II;
NS, not significant.
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BMI (≥27.7 kg/m2) were associated with the risk of failed
and unreliable measurements of ARFI (Bota et al. 2014).
In the present study, BMI was ≥ 27.7 kg/m2 in 17 patients.
Thus we analyzed the 214 patients with BMI < 27.7 kg/m2.
Multivariate analysis showed that older age (OR = 1.06;
95% CI: 1.03–1.09; p = 0.0001), higher BMI (OR = 1.11;
95% CI: 1.00–1.24; p = 0.0576), and PNPLA3 genotype
GG (OR = 2.07; 95% CI: 0.94–4.55; p = 0.0712) were fac-
tors independently associated with progression to cirrhosis
(data not shown). The standard range of BMI is 18.5 –
24.9 kg/m2. Thus we analyzed 154 patients with BMI of
18.5 – 24.9 kg/m2. Neither univariate nor multivariate
analysis showed the association of PNPLA3 genotype with
cirrhosis (data not shown).
The mechanism underlying the association between a
PNPLA3 gene polymorphism with the progression of stea-
tosis, fibrosis, and development of HCC has not been de-
termined. It was recently reported that a PNPLA3 I148M
variant promotes the synthesis of hepatic lipid because of
a gain of function (Kumari et al. 2012). Steatosis main-
tained by the PNPLA3 genotype I148M may promote the
progression of fibrosis and development of HCC (Valenti
et al. 2011; Trepo et al. 2011; Valenti et al. 2012).Conclusions
In this study, we confirmed that the PNPLA3 genotype
I148M was associated with the development of HCC in
Japanese patients with CHC, and is one of risk factors
for cirrhosis in the patients without past history of IFN
treatment. Further studies are required to clarify the
mechanism underlying this association.Methods
Patients
Two hundred thirty-one patients with chronic HCV in-
fection consulted with the Department of Liver, Biliary
Tract and Pancreas Diseases, Fujita Health University
Hospital from May 2010 to October 2012 (Table 1). Of
these patients, 137 had no past history of IFN treatment.
The other 94 patients had a past history of IFN treat-
ment, for which HCV RNA did not become negative
during treatment and their results were considered as
NVR. The patients with a past history of IFN treatment
and who had achieved a SVR or relapse, which indicated
temporary HCV RNA negativity during the treatment,
were excluded from the present study because their
LSM results declined and the risk of the development of
Table 7 Comparison between the patients with HCC and those without HCC in the 94 patients with NVR of past IFN
treatment
Patients with HCC Patients without HCC Comparison between
patients with HCC and
those without HCC
Multiple regression analysis for factors
associated with HCC development
(n = 17) (n = 77) Odds ratio (95%
confidence interval)
p
Age (yrs) 69.6±9.3 58.9±10.0 P = 0.0001 1.19 (1.08 - 1.32) p = 0.0007
Gender (male/female) 9/8 47/30 NS NS
BMI (kg/m2) 23.2±3.8 22.9±3.3 NS
PNPLA3 (GG/CC・CG) 6/11 13/64 P = 0.0871 3.95 (1.00 - 15.61) p = 0.0497
AST (IU/L) 56.35±25.5 55.3±52.3 NS
ALT (IU/L) 51.1±38.6 63.0±80.0 NS
γ-GTP (IU/L) 44.8±20.6 63.1±100.8 NS
Albumin (g/dL) 3.5±1.0 4.3±0.4 p < 0.0001
Total bilirubin (mg/dL) 0.9±0.5 0.9±1.1 NS
Platelet count (x104/μL) 10.1±4.1 14.9±5.4 P = 0.0008
Prothrombin time (%) 88.0±14.2 98.4±17.3 P = 0.0295
Hyaluronic acid (ng/mL) 402.2±316.9 153.1±186.6 P = 0.0002
α-fetoprotein (ng/mL) 23.2±20.6 9.8±12.1 P = 0.0005
PIVKA-II(mAU/mL) 28.0±19.4 20.2±8.9 P = 0.0134
HCV genotype (1/2/3) 16/1/0 63/13/1 NS
HCV RNA (log IU/mL) 6.2±1.2 6.2±1.1 NS
Velocity of shear wave (m/s) 2.20±0.70 1.60±0.5 P = 0.0002
HCC, hepatocellular carcinoma; IFN, interferon; NVR, non-virological response; BMI, body mass index; PNPLA3, patatin-like phospholipase domain-containing 3;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II;
NS, not significant.
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1998; Harada et al. 2014).
In addition, patients with hepatitis B virus coinfection,
human immunodeficiency virus coinfection, alcoholic
liver disease, or autoimmune liver disease were not in-
cluded in the study. This study was approved by the ethics
committee of the Fujita Health University and was con-
ducted in accordance with the Declaration of Helsinki of
1975, as revised in 2008. All patients who participated in
this study had provided written informed consent.
PNPLA3 rs738409 genotyping
Genomic DNA was extracted from whole blood samples
using QIA amp DNA Mini Kits (Qiagen, Tokyo, Japan),
according to the manufacturer’s protocol. The rs738409
PNPLA3 SNP was genotyped using TaqMan predesigned
SNP genotyping assays (Applied Biosystems, Tokyo,
Japan), according to the manufacturer’s protocol.
ARFI measurements
Vs measurements by ARFI were made with a Siemens
ACUSON S2000 (Siemens Japan Co., Ltd., Tokyo, Japan)
as previously reported (Nishikawa et al. 2014). Vs values
were expressed in meters/second (m/s), and was con-sidered to be proportional to the square root of tissue
elasticity.
Statistical analysis
Results are expressed as means ± standard deviations.
Group results were compared using chi-square test or
Student’s t-test, as appropriate. Bonferroni corrections
were used during multiple group comparisons. Factors
possibly associated with Vs of ≥1.55 m/s or with the de-
velopment of HCC were assessed using stepwise logistic
regression analysis. Statistical analysis was performed
using the StatFlex version 5.0 for Windows (StatFlex,
Osaka Japan). A two-sided p-value of <0.05 was con-
sidered significant.
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